Manufacturers claim that gene patents, which now cover 25-40% of the human genome, are vital to recouping their investments.
Os fabricantes afirmam que as patentes de genes, que actualmente cobrem 25% a 40% do genoma humano, são fundamentais para que possam recuperar os seus investimentos.